It’s ceratinly been an intense and busy weekend covering early-stage new product developments at ESMO this year.

As with every new crop of agents, some look more promising than others with the abstract drops only to fizzle when we see the presentations, while other seem nondescript initially then provide hidden depths with the data reveal.

This year’s meeting from Barcelona is no different, offering highs and lows in equal measure.

In our latest review, we put half a dozen agents through their paces and explain the whys and wherefores to watch out for…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by